Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.

Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, Cooper D, Lange J, Harris M, Wainberg MA, Robinson P, Myers M, Hall D.

AIDS. 1998 Sep 10;12(13):1619-24.

PMID:
9764780
[PubMed - indexed for MEDLINE]
2.

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM.

JAMA. 1998 Mar 25;279(12):930-7.

PMID:
9544767
[PubMed - indexed for MEDLINE]
3.

Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.

Raboud JM, Rae S, Vella S, Harrigan PR, Bucciardini R, Fragola V, Ricciardulli D, Montaner JS.

J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):260-6.

PMID:
10770346
[PubMed - indexed for MEDLINE]
4.

Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation.

Raboud JM, Rae S, Hogg RS, Yip B, Sherlock CH, Harrigan PR, O'Shaughnessy MV, Montaner JS.

J Infect Dis. 1999 Oct;180(4):1347-50.

PMID:
10479170
[PubMed - indexed for MEDLINE]
Free Article
5.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):55-60.

PMID:
9732070
[PubMed - indexed for MEDLINE]
6.

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS.

Ann Intern Med. 1996 Jun 15;124(12):1019-30.

PMID:
8633815
[PubMed - indexed for MEDLINE]
7.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
[PubMed - indexed for MEDLINE]
8.

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.

PMID:
11730396
[PubMed - indexed for MEDLINE]
10.

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.

Pakker NG, Kroon ED, Roos MT, Otto SA, Hall D, Wit FW, Hamann D, van der Ende ME, Claessen FA, Kauffmann RH, Koopmans PP, Kroon FP, ten Napel CH, Sprenger HG, Weigel HM, Montaner JS, Lange JM, Reiss P, Schellekens PT, Miedema F.

AIDS. 1999 Feb 4;13(2):203-12.

PMID:
10202826
[PubMed - indexed for MEDLINE]
11.

The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.

Raffi F, Reliquet V, Ferré V, Arvieux C, Hascoet C, Bellein V, Besnier JM, Breux JP, Garré M, May T, Molina JM, Perré P, Raguin G, Rozenbaum W, Zucman D.

Antivir Ther. 2000 Dec;5(4):267-72.

PMID:
11142621
[PubMed - indexed for MEDLINE]
12.

Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.

Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.

AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1631-8.

PMID:
10606086
[PubMed - indexed for MEDLINE]
13.

A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J.

Antivir Ther. 2002 Jun;7(2):81-90.

PMID:
12212928
[PubMed - indexed for MEDLINE]
15.

Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.

Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS.

AIDS. 2000 Apr 14;14(6):671-81. Erratum in: AIDS 2000 Jun 16;14(9):1295.

PMID:
10807190
[PubMed - indexed for MEDLINE]
16.

Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.

de Mendoza C, Soriano V, Pérez-Olmeda M, Rodríguez-Rosado R, González-Lahoz J.

J Hum Virol. 2000 Nov-Dec;3(6):335-40.

PMID:
11100914
[PubMed - indexed for MEDLINE]
17.

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

Wood E, Hogg RS, Yip B, Tyndall MW, Sherlock CH, Harrigan RP, O'Shaughnessy MV, Montaner JS.

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):159-66.

PMID:
12045678
[PubMed - indexed for MEDLINE]
18.

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.

Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM; ACTG 303 Study Team.

AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1337-44.

PMID:
11018853
[PubMed - indexed for MEDLINE]
19.

Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy.

Wood E, Yip B, Hogg RS, Sherlock CH, Jahnke N, Harrigan RP, O'Shaughnessy MV, Montaner JS.

AIDS. 2000 Sep 8;14(13):1955-60.

PMID:
10997400
[PubMed - indexed for MEDLINE]
20.

Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.

de Mendoza C, Soriano V, Pérez-Olmeda M, Rodés B, Casas E, González-Lahoz J.

J Hum Virol. 1999 Nov-Dec;2(6):344-9.

PMID:
10774551
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk